U.S. District Judge Matthew Kennelly ordered a new trial in the first bellwether against AbbVie Inc., in a multidistrict litigation accusing testosterone replacement therapy manufacturers of failing to warn of cardiovascular risks, finding that the jury must have misunderstood the issue of causation. Plaintiff Jesse Mitchell claimed AbbVie’s testosterone treatment AndroGel was not adequately tested to better understand its cardiovascular risks. Despite this, the company aggressively marketed the drug for the off-label treatment of a made-up condition they called Low T. The jury awarded Mitchell $150 million in punitive damages, finding the company misrepresented its testosterone therapy. But the jury ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.